

AMENDMENTS TO THE CLAIMS

This listing of claims will replace all prior versions, and listings, of claims in the application.

1-43. (Cancelled)

44. (Currently amended) A pharmaceutical composition comprising a first humanized monoclonal antibody that ~~and second antibody of claim 1 and a pharmaceutically acceptable carrier or diluent, wherein the first antibody of claim 1~~ specifically binds to Shiga toxin type 2 (Stx2) antigen and a second humanized monoclonal antibody that specifically binds to Shiga toxin type 1 (Stx1) antigen, wherein the first antibody ~~and~~ comprises a variable region consisting of the immunoglobulin heavy chain and light chain variable regions as set forth in SEQ ID NOs: 42 and 44 and the second antibody ~~of claim 1 specifically binds to Stx1 antigen and~~ comprises a variable region consisting of the immunoglobulin heavy chain and light chain variable regions as set forth in SEQ ID NOs: 19 and 21.

45-53. (Cancelled)

54. (Currently amended) The pharmaceutical composition of claim ~~44~~ 47, wherein the first or second antibody comprises a human constant region selected from the group consisting of IgG, IgA, and IgM ~~said humanized antibody of claim 19 that specifically binds to Stx2 antigen or Stx2 antigen variants, comprises an IgG1 kappa human immunoglobulin constant region.~~

55. (Currently amended) The pharmaceutical composition of claim ~~47~~ 54,

wherein the human constant region of the first or second antibody is an said humanized antibody that specifically binds to Stx1 antigen comprises an IgG1 kappa human immunoglobulin constant region.

.56. (Cancelled)

57. (Currently amended) A The pharmaceutical composition comprising the antibody of claim 44 56 and a wherein the composition further comprises a pharmaceutically acceptable carrier or diluent.

58-60. (Cancelled)

61. (Currently amended) ~~The~~ A pharmaceutical composition ~~of claim 57,~~ further comprising a first humanized monoclonal antibody that specifically binds to Stx1 antigen and a second humanized monoclonal antibody that specifically binds to Stx2 antigen, wherein the variable region of the first monoclonal antibody comprises a human immunoglobulin constant region and a variable region, wherein said variable region consists of the murine 13C4 (ATCC Accession No. CRL 1794) heavy chain and light chain variable regions and wherein the variable region of the second said humanized monoclonal antibody that specifically binds to Stx2 antigen comprises a human immunoglobulin constant region and a variable region, wherein said variable region consists of the murine 11E10 (ATCC Accession No. CRL 1907) heavy chain and light chain variable regions region.

62. (Currently amended) The pharmaceutical composition of claim 61, wherein wherein the first or second antibody comprises a human constant region selected from the group consisting of IgG, IgA, and IgM said humanized monoclonal antibody that

~~specifically binds to Stx1 antigen or Stx1 antigen variants comprises an IgG1 kappa human immunoglobulin constant region.~~

63. (Currently amended) The pharmaceutical composition of claim ~~62~~ 61, wherein the human constant region of the first or second antibody is ~~wherein said humanized antibody that specifically binds to Stx2 antigen comprises an IgG1 kappa human immunoglobulin constant region.~~

64. (New) The pharmaceutical composition of claim 61, wherein the composition further comprises a pharmaceutically acceptable carrier or diluent.